Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

[Clinical manifestations of pneumococcal infections and the current prevention options].

Kosina P, Rumlarová Š, Plíšek S, Smetana J.

Klin Mikrobiol Infekc Lek. 2013 Dec;19(4):120-7. Czech.

PMID:
24623052
[PubMed - in process]
2.
3.

Pneumococcal conjugate vaccine for young children.

Selman S, Hayes D, Perin LA, Hayes WS.

Manag Care. 2000 Sep;9(9):49-52, 54, 56-7 passim. Review.

PMID:
11116663
[PubMed - indexed for MEDLINE]
Free Article
4.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
[PubMed - indexed for MEDLINE]
5.

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.

PMID:
24606865
[PubMed - in process]
6.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

PMID:
22954038
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices.

MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6.

PMID:
20814406
[PubMed - indexed for MEDLINE]
Free Article
8.

Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?

Metersky ML, Dransfield MT, Jackson LA.

Chest. 2010 Sep;138(3):486-90. doi: 10.1378/chest.10-0738. Epub 2010 Jun 24.

PMID:
20576729
[PubMed - indexed for MEDLINE]
9.

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea.

Choi EH, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, Eun BW, Jo DS, Choi KM, Hong YJ.

Korean J Pediatr. 2011 Apr;54(4):146-51. doi: 10.3345/kjp.2011.54.4.146. Epub 2011 Apr 30.

PMID:
21738547
[PubMed]
Free PMC Article
10.

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

American Academy of Pediatrics Committee on Infectious Diseases.

Pediatrics. 2010 Jul;126(1):186-90. doi: 10.1542/peds.2010-1280. Epub 2010 May 24.

PMID:
20498180
[PubMed - indexed for MEDLINE]
Free Article
11.

Advances in pneumococcal vaccines: what are the advantages for the elderly?

Vila-Córcoles A.

Drugs Aging. 2007;24(10):791-800. Review.

PMID:
17896829
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D.

BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

PMID:
22530841
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

PMID:
22357831
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.

Mokaddas E, Albert MJ.

Vaccine. 2012 Dec 31;30 Suppl 6:G37-40. doi: 10.1016/j.vaccine.2012.10.061.

PMID:
23228356
[PubMed - indexed for MEDLINE]
15.

The future of pneumococcal disease prevention.

Rodgers GL, Klugman KP.

Vaccine. 2011 Sep 14;29 Suppl 3:C43-8. doi: 10.1016/j.vaccine.2011.07.047.

PMID:
21896352
[PubMed - indexed for MEDLINE]
16.

Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).

Shibl AM, Memish ZA, Al-Kattan KM.

Vaccine. 2012 Dec 31;30 Suppl 6:G32-6. doi: 10.1016/j.vaccine.2012.07.030.

PMID:
23228355
[PubMed - indexed for MEDLINE]
17.

Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.

Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R.

Pediatr Infect Dis J. 2009 Apr;28(4):277-82. doi: 10.1097/INF.0b013e31818e0e2e.

PMID:
19258924
[PubMed - indexed for MEDLINE]
18.

Pneumococcal vaccines. WHO position paper.

[No authors listed]

Wkly Epidemiol Rec. 1999 Jun 11;74(23):177-83. English, French.

PMID:
10437429
[PubMed - indexed for MEDLINE]
19.

Vaccination against pneumococcus in West Africa: perspectives and prospects.

Donkor ES, Dayie NT, Badoe EV.

Int J Gen Med. 2013 Sep 11;6:757-64. doi: 10.2147/IJGM.S45842. eCollection 2013.

PMID:
24049454
[PubMed]
Free PMC Article
20.

Pneumococcal vaccines: World Health Organization position paper.

[No authors listed]

Can Commun Dis Rep. 1999 Sep 1;25(17):150-1. English, French.

PMID:
10513118
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk